

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/I48027E3102EN.html>

Date: November 2019

Pages: 88

Price: US\$ 2,000.00 (Single User License)

ID: I48027E3102EN

Abstracts

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis - Pipeline Review, H2 2019, provides an overview of the Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline landscape.

Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience bladder pressure, bladder pain and sometimes pelvic pain, ranging from mild discomfort to severe pain. Symptoms include decreased bladder capacity, painful sexual intercourse, chronic pelvic pain and a persistent, urgent need to urinate. Risk factors include age, gender and chronic pain disorder, such as irritable bowel syndrome or fibromyalgia. Treatment includes non-steroidal anti-inflammatory drug, antidepressants and antihistamines.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Interstitial Cystitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 2, 4, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Genito Urinary System And Sex Hormones).

The pipeline guide reviews pipeline therapeutics for Interstitial Cystitis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Interstitial Cystitis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Interstitial Cystitis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Genito Urinary System And Sex Hormones)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Interstitial Cystitis (Genito Urinary System And Sex Hormones).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Overview

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Therapeutics
Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Therapeutics
Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Companies

Involved in Therapeutics Development

Alivio Therapeutics Inc

GlycoMira Therapeutics Inc

Grunenthal GmbH

Harrow Health Inc

Kyorin Pharmaceutical Co Ltd

Lipella Pharmaceuticals Inc

Mirae Cell Bio Co Ltd

Pierre Fabre Pharmaceuticals Inc

UCB SA

Urogen Pharmaceuticals Inc

Xigen SA

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Drug Profiles

(heparin sodium + lidocaine hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brimapitide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

certolizumab pegol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dimethyl sulfoxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-16357 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-0111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRT-6010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LP-08 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAY-88 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-5937 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentosan polysulfate sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URG-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Dormant Projects

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Discontinued Products

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Product Development Milestones

Featured News & Press Releases

Oct 08, 2019: Mayfield Pharmaceuticals to Present update on MAY-88 drug candidate at the SVB Leerink New Treatments Focused on Women's Health Conference

Sep 12, 2018: U.S. Department of Defense awards \$3.3 million grant to Alivio Therapeutics

Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis

May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms

Jun 30, 2011: Urogen Provides Development Update For URG101

Aug 18, 2010: Urogen Reports Type C Meeting With FDA For URG101

Aug 11, 2010: Urogen Announces FDA Follow Up For URG101 Program For Treatment Of Interstitial Cystitis

Apr 23, 2010: Urogen Files Request For FDA Meeting

Dec 29, 2008: Urogen Amends Its Core UCSD License For URG101

Aug 20, 2008: Urogen Announces Issuance Of Key Patent To URG101 For Interstitial Cystitis

Apr 25, 2008: Urogen Announces US Patent Office Notice Of Allowance Of Claims For

URG101

Apr 07, 2008: Urogen Announces Early Closure Of URG101 Phase II Clinical Trial based On Positive Interim Analysis Results

Dec 05, 2007: Urogen Pharmaceuticals and Hyaluron Contract Manufacturing, Inc. Enter Into Drug Development Agreement For URG101

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Alivio Therapeutics Inc, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by GlycoMira Therapeutics Inc, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Grunenthal GmbH, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Harrow Health Inc, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Lipella Pharmaceuticals Inc, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Mirae Cell Bio Co Ltd, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Pierre Fabre Pharmaceuticals Inc, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by UCB SA, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Urogen Pharmaceuticals Inc, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Xigen SA, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Dormant Projects, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Discontinued

Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Alivio Therapeutics Inc
GlycoMira Therapeutics Inc
Grunenthal GmbH
Harrow Health Inc
Kyorin Pharmaceutical Co Ltd
Lipella Pharmaceuticals Inc
Mirae Cell Bio Co Ltd
Pierre Fabre Pharmaceuticals Inc
UCB SA
Urogen Pharmaceuticals Inc
Xigen SA

I would like to order

Product name: Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/l48027E3102EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l48027E3102EN.html>